Naxagolide (BioDeep_00000720009)

   


代谢物信息卡片


Naxagolide

化学式: C15H21NO2 (247.15722060000002)
中文名称: 那高利特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCCN1CCOC2C1CCC3=C2C=C(C=C3)O
InChI: InChI=1S/C15H21NO2/c1-2-7-16-8-9-18-15-13-10-12(17)5-3-11(13)4-6-14(15)16/h3,5,10,14-15,17H,2,4,6-9H2,1H3/t14-,15-/m1/s1

描述信息

D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist
Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD)[1][2].

同义名列表

3 个代谢物同义名

Naxagolide; (+)-PHNO; Dopazinol



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Amane Tateno, Takeshi Sakayori, Woo-Chan Kim, Kazuyoshi Honjo, Haruo Nakayama, Ryosuke Arakawa, Yoshiro Okubo. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO. The international journal of neuropsychopharmacology. 2018 06; 21(6):522-527. doi: 10.1093/ijnp/pyy004. [PMID: 29346639]
  • Doris Payer, Belinda Williams, Esmaeil Mansouri, Suzanna Stevanovski, Shinichiro Nakajima, Bernard Le Foll, Stephen Kish, Sylvain Houle, Romina Mizrahi, Susan R George, Tony P George, Isabelle Boileau. Corticotropin-releasing hormone and dopamine release in healthy individuals. Psychoneuroendocrinology. 2017 02; 76(?):192-196. doi: 10.1016/j.psyneuen.2016.11.034. [PMID: 27951520]
  • Ragy R Girgis, Mark Slifstein, Deepak D'Souza, Yih Lee, Antonia Periclou, Parviz Ghahramani, István Laszlovszky, Suresh Durgam, Nika Adham, Nabeel Nabulsi, Yiyun Huang, Richard E Carson, Béla Kiss, Margit Kapás, Anissa Abi-Dargham, Ashok Rakhit. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology. 2016 Oct; 233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. [PMID: 27525990]
  • Bernard Le Foll, Doris Payer, Patricia Di Ciano, Mihail Guranda, Shinichiro Nakajima, Junchao Tong, Esmaeil Mansouri, Alan A Wilson, Sylvain Houle, Jeff H Meyer, Ariel Graff-Guerrero, Isabelle Boileau. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2016 Jan; 41(2):529-37. doi: 10.1038/npp.2015.177. [PMID: 26089182]
  • Jean-Dominique Gallezot, Ming-Qiang Zheng, Keunpoong Lim, Shu-fei Lin, David Labaree, David Matuskey, Yiyun Huang, Yu-Shin Ding, Richard E Carson, Robert T Malison. Parametric Imaging and Test-Retest Variability of ¹¹C-(+)-PHNO Binding to D₂/D₃ Dopamine Receptors in Humans on the High-Resolution Research Tomograph PET Scanner. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2014 Jun; 55(6):960-6. doi: 10.2967/jnumed.113.132928. [PMID: 24732151]
  • Christophe Plisson, Mickael Huiban, Sabina Pampols-Maso, Görkem Singleton, Samuel P Hill, Jan Passchier. Automated preparation of the dopamine D2/3 receptor agonist ligand [11C]-(+)-PHNO for human PET imaging studies. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2012 Feb; 70(2):380-7. doi: 10.1016/j.apradiso.2011.09.018. [PMID: 22055845]
  • Ragy R Girgis, Xiaoyan Xu, Nobumi Miyake, Balu Easwaramoorthy, Roger N Gunn, Eugenii A Rabiner, Anissa Abi-Dargham, Mark Slifstein. In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2011 Mar; 36(4):887-95. doi: 10.1038/npp.2010.228. [PMID: 21178982]
  • Patrick N McCormick, Shitij Kapur, Philip Seeman, Alan A Wilson. Dopamine D2 receptor radiotracers [(11)C](+)-PHNO and [(3)H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nuclear medicine and biology. 2008 Jan; 35(1):11-7. doi: 10.1016/j.nucmedbio.2007.08.005. [PMID: 18158938]
  • Philip Seeman. Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2(High) receptors. Synapse (New York, N.Y.). 2007 Dec; 61(12):1013-8. doi: 10.1002/syn.20453. [PMID: 17853435]
  • Philip Seeman, Françoise Ko, Matthäus Willeit, Patrick McCormick, Nathalie Ginovart. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Synapse (New York, N.Y.). 2005 Nov; 58(2):122-8. doi: 10.1002/syn.20193. [PMID: 16088951]
  • R J Coleman, K W Lange, N P Quinn, A E Loper, J V Bondi, M Hichens, S M Stahl, C D Marsden. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Movement disorders : official journal of the Movement Disorder Society. 1989; 4(2):129-38. doi: 10.1002/mds.870040204. [PMID: 2733705]
  • C M Gust, S K Hemrick-Luecke, R W Fuller. Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist. Journal of neural transmission. 1989; 75(1):11-20. doi: 10.1007/bf01250640. [PMID: 2563751]
  • C M Gust, R W Fuller. Further characterization of tolerance to the corticosterone-elevating effect of pergolide in rats. Neuroscience letters. 1988 Nov; 93(2-3):307-11. doi: 10.1016/0304-3940(88)90100-0. [PMID: 2907374]
  • D G Musson, R J Tobias, B K Maglietto, H G Ramjit, W F Bayne. A sensitive gas chromatographic mass spectrometric assay for a novel dopamine agonist (+)-trans-3,4,4A,5,6,10B-hexahydro-4-propyl-2H-naphth(1,2-B)(1,4) oxazin-9-ol in human plasma. Biomedical & environmental mass spectrometry. 1988 Oct; 17(4):293-8. doi: 10.1002/bms.1200170411. [PMID: 2903777]